LEADER 01971nam  2200469   450 
001 9910162849903321
005 20230808201433.0
010   $a1-58040-653-X
035   $a(CKB)3710000001044436
035   $a(MiAaPQ)EBC4552627
035   $a(EXLCZ)993710000001044436
100   $a20150807h20162016  uy|            0
101 0 $aeng
135   $aurcnu||||||||
181   $2rdacontent
182   $2rdamedia
183   $2rdacarrier
200 10$aDiabetes risks from prescription & non-prescription drugs $emechanisms and approaches to risk reduction /$fSam Dagogo-Jack
210  1$aAlexandria :$cAmerican Diabetes Association,$d[2016]
210  4$dİ2016
215   $a1 online resource (145 pages) $cillustrations
311   $a1-58040-619-X 
320   $aIncludes bibliographical references and index.
327   $aOverview of diagnosis, classification, and pathophysiology of diabetes -- Medications and diabetes risk : general mechanisms -- Steroids and immunomodulatory agents -- Antihypertensive agents -- Catecholamines, [alpha]-adrenergic agonists, and bronchodilators -- Lipid-lowering agents -- Antimicrobial agents -- Atypical antipsychotic and antidepressant agents -- Recreational drugs : alcohol, nicotine, marijuana, and cannabinoids, opioids, cocaine -- Miscellaneous agents -- General approach to risk reduction.
606   $aDiabetes$xEtiology
606   $aPrediabetic state
606   $aDrugs$xSide effects
606   $aDrugs$xRisk assessment
615  0$aDiabetes$xEtiology.
615  0$aPrediabetic state.
615  0$aDrugs$xSide effects.
615  0$aDrugs$xRisk assessment.
676   $a616.4/62061
700   $aDagogo-Jack$b Sam$f1954-$01243207
712 02$aAmerican Diabetes Association,
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910162849903321
996   $aDiabetes risks from prescription & non-prescription drugs$92883668
997   $aUNINA